EDIT:NASDAQEditas Medicine, Inc. Analysis
Data as of 2026-09-27 - not real-time
$2.58
Latest Price
9/10Risk
Risk Level: High
Executive Summary
Editas Medicine, Inc. is priced at $2.58, and its moving averages give no clean directional read — the structure is neutral. Over a rolling month the price has lost 8.2%. With RSI at 40.8 the momentum picture is neutral, alongside a bearish MACD signal. Price has been bracketed by support at $2.55 and resistance at $3.41.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 128.7% above the current price. Revenue is growing at 232.3% on a -157.3% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 81.5%, a beta of 2.19 and a maximum drawdown of 59.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 3 out of 10.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. Analyst price targets sit 128.7% above the current price. Revenue is growing at 232.3% on a -157.3% profit margin.
The composite risk read is 9/10, putting it in high territory. With 30-day volatility of 81.5%, a beta of 2.19 and a maximum drawdown of 59.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Timeframes disagree: the short-term read is sell while the long-term read is hold, conviction 3 out of 10.
Top Market Events
CAMBRIDGE, Mass., Sept. 01, 2026 GLOBE NEWSWIRE -- Editas Medicine, Inc. Nasdaq: EDIT , a pioneering gene editing...Editas EDIT reported earnings 30 days ago.CAMBRIDGE, Mass., Sept. 09, 2026 GLOBE NEWSWIRE -- Editas Medicine, Inc. Nasdaq: EDIT , a pioneering gene editing...
Market Outlook
Short Term
< 1 yearCautious
Model confidence: 4/10
Key Factors
- Trading below the 200-day average of 2.64
- MACD momentum is negative
- 30-day price change of -8.2%
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Trading below the 200-day average of 2.64
- Analyst targets imply +128.7% versus the current price
- 30-day volatility of 81.5%
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- Negative profit margin of -157.3%
- Analyst targets imply +128.7% versus the current price
- Negative return on equity of -118.8%
Key Metrics & Analysis
Financial Health
Revenue Growth232.30%
Profit Margin-157.32%
P/E Ratio-3.4
ROE-118.82%
ROA-23.29%
Debt/Equity14.73
P/B Ratio3.8
Op. Cash Flow$-119859000
Free Cash Flow$-44316000
Industry P/E30.5
Technical Analysis
TrendNeutral
RSI40.8
Support$2.55
Resistance$3.41
MA 20$2.86
MA 50$2.86
MA 200$2.64
MACDBearish
VolumeIncreasing
Fear & Greed Index94.88
Valuation
Target Price$5.90
Upside/Downside128.68%
GradeFair
TypeGrowth
Risk Assessment
Beta2.19
Volatility81.48%
Sector RiskMedium
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.